NICE has issued an update to its HTG274 (previously DG59) guidance page covering CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack, incorporating new information from the completion of the national pilot study and clarifying the current position on national commissioning.
Please note: The testing is not currently nationally commissioned.
The updated NICE HTG274 landing page Overview | CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack | Guidance | NICE provides the official overview and latest position as well as links to supporting and related resources for CYP2C19-clopidogrel testing, including the implementation guide published by the NHS Pharmacogenomics and Medicines Optimisation Network of Excellence.